公开(公告)号：US20230213360A1

公开(公告)日：2023-07-06

申请号：US18091219

申请日：2022-12-29

Applicant: University of Washington

Inventor： Jae-Hyun Chung ,  Sang-Gyeun Ahn ,  Tianyi Li ,  Zhongjie Qian ,  Vigneshwar Sakthivelpathi

IPC: G01D5/24 ,  G06F3/01 ,  G01F22/02

CPC classification number: G01D5/24 ,  G06F3/011 ,  G01F22/02

Abstract: A capacitive sensor including an electrically conductive material, and a single electrode applied with positive potential, wherein the distance between the single electrode and the electrically conductive material determines the spherical radius for a proximity sensing range.

公开(公告)号：US20230210816A1

公开(公告)日：2023-07-06

申请号：US17998800

申请日：2021-05-24

Applicant: UNIVERSITY OF WASHINGTON ,  UNIVERSITY OF VIRGINIA PATENT FOUNDATION

Inventor： Stephen J. Polyak ,  Shawn Herring ,  Jessica Wagoner ,  Judith White

IPC: A61K31/4045 ,  A61K31/496 ,  A61K31/47 ,  A61K31/135 ,  A61K9/00 ,  A61P31/14

CPC classification number: A61K31/4045 ,  A61K31/496 ,  A61K31/47 ,  A61K31/135 ,  A61K9/0053 ,  A61P31/14

Abstract: Methods for inhibiting or treating viral infection in a subject infected with a vims of the arenaviridae family with a therapeutic agent combination: (a) arbidol and aripiprazole; (b) arbidol and amodiaquine; (c) arbidol and sertraline; (d) arbidol, iprazole, and amodiaquine; (e) arbidol, aripiprazole, and sertraline; or (f) aripiprazole and amodiaquine; or pharmaceutically acceptable salts thereof.

公开(公告)号：US20230193351A1

公开(公告)日：2023-06-22

申请号：US17814771

申请日：2022-07-25

Applicant: University of Washington

Inventor： Georg Seelig ,  Richard Muscat ,  Alexander B. Rosenberg

IPC: C12Q1/6806 ,  C12Q1/6855 ,  C12N15/10

CPC classification number: C12Q1/6806 ,  C12N15/1065 ,  C12Q1/6855

Abstract: Methods of uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are provided. Kits for uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are also provided. The molecules to be labeled may include, but are not limited to, RNAs, cDNAs, DNAs, proteins, peptides, and/or antigens.

公开(公告)号：US11680283B2

公开(公告)日：2023-06-20

申请号：US16649601

申请日：2018-09-21

Applicant: UNIVERSITY OF WASHINGTON

Inventor： Georg Seelig ,  Alexander B. Rosenberg ,  Charles Roco

IPC: C12Q1/6806

CPC classification number: C12Q1/6806 ,  C12Q2521/107 ,  C12Q2525/161 ,  C12Q2543/101 ,  C12Q2563/179 ,  C12Q2563/185 ,  C12Q2565/514

Abstract: Methods of uniquely labeling or barcoding molecules within a nucleus, a plurality of nuclei, a cell, a plurality of cells, and/or a tissue are provided. Kits for uniquely labeling or barcoding molecules within a nucleus, a plurality of nuclei, a cell, a plurality of cells, and/or a tissue are also provided. The molecules to be labeled may include, but are not limited to, RNAs and/or cDNAs.

公开(公告)号：US11667972B2

公开(公告)日：2023-06-06

申请号：US17392180

申请日：2021-08-02

Applicant: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION

Inventor： Jesse Salk ,  Lawrence A. Loeb ,  Michael Schmitt

IPC: C12Q1/68 ,  C12Q1/6876 ,  C12Q1/6806 ,  C12Q1/6869

CPC classification number: C12Q1/6876 ,  C12Q1/6806 ,  C12Q1/6869 ,  C12Q1/6869 ,  C12Q2525/179 ,  C12Q2525/185 ,  C12Q2525/191 ,  C12Q2535/119 ,  C12Q1/6806 ,  C12Q2525/191 ,  C12Q2535/119 ,  C12Q2535/122 ,  C12Q2563/179 ,  C12Q2565/514

Abstract: Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand. This method uniquely capitalizes on the redundant information stored in double-stranded DNA, thus overcoming technical limitations of prior methods utilizing data from only one of the two strands.

公开(公告)号：US20230147744A1

公开(公告)日：2023-05-11

申请号：US17916683

申请日：2021-04-05

Applicant: The University of North Carolina at Chapel Hill ,  University of Washington

Inventor： Nancy L. Allbritton ,  Yuli Wang ,  Christopher E. Sims ,  Cecilia Villegas Novoa

IPC: C12N5/071 ,  C12M1/12

CPC classification number: C12N5/0679 ,  C12M25/04 ,  C12N2501/30 ,  C12N2503/02 ,  C12N2501/415

Abstract: Provided are new strategies, methods and systems, described herein as vasoactive intestinal peptide (VIP)-assisted air-liquid-interface (ALI) culture, to significantly increase the number of enteroendocrine (EEC) and enterochromaffin (EC) cells over the traditional submerged culture, while at the same time maintaining a high barrier integrity of monolayers. The new strategies, methods and systems overcome the limitations of the existing EEC enrichment methods by maintaining high cell viability and barrier integrity and without requiring complicated procedures of cocultures or genetic engineering/induction. The created EEC-enriched, contiguous monolayer platform acts as a robust analytical tool to enable functional studies of hormone secretion from EEC cells with high signal background ratio and repeatability.

公开(公告)号：US11644656B2

公开(公告)日：2023-05-09

申请号：US17737736

申请日：2022-05-05

Applicant: University of Washington

Inventor： Adam K. Glaser ,  Jonathan T. C. Liu

IPC: G02B21/00 ,  G02B21/06 ,  G02B21/02 ,  G02B21/33 ,  G02B21/36

CPC classification number: G02B21/06 ,  G02B21/02 ,  G02B21/33 ,  G02B21/361

Abstract: Apparatuses, systems, and methods for an open-top light-sheet (OTLS) microscope which includes an illumination objective and a collection objective which have optical axes which are non-orthogonal to each other. The optical axis of the collection objective may be orthogonal to a plane of the sample holder. The illumination and collection objective may be located below the sample holder. The OTLS microscope may optionally include a second collection objective which has an optical axis orthogonal to the optical axis of the illumination objective. The illumination objective may be an air objective, and the collection objective may be an immersion objective.

公开(公告)号：US11643686B2

公开(公告)日：2023-05-09

申请号：US17392193

申请日：2021-08-02

Applicant: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION

Inventor： Jesse Salk ,  Lawrence A. Loeb ,  Michael Schmitt

IPC: C12Q1/6876 ,  C12Q1/6806 ,  C12Q1/6869

CPC classification number: C12Q1/6876 ,  C12Q1/6806 ,  C12Q1/6869 ,  C12Q1/6869 ,  C12Q2525/179 ,  C12Q2525/185 ,  C12Q2525/191 ,  C12Q2535/119 ,  C12Q1/6806 ,  C12Q2525/191 ,  C12Q2535/119 ,  C12Q2535/122 ,  C12Q2563/179 ,  C12Q2565/514

Abstract: Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand. This method uniquely capitalizes on the redundant information stored in double-stranded DNA, thus overcoming technical limitations of prior methods utilizing data from only one of the two strands.

公开(公告)号：US20230137595A1

公开(公告)日：2023-05-04

申请号：US17978764

申请日：2022-11-01

Applicant: University of Washington

Inventor： Rajesh P.N. Rao

IPC: A61N1/36 ,  A61N1/02 ,  G16H40/63 ,  G06N20/00

Abstract: Restoring and/or augmenting neural function may be achieved in some examples by receiving signals associated with a first region of a nervous system, and generating a stimulation pattern based on the signals associated with the first region of the nervous system and a first artificial network. The stimulation pattern may be provided to a second region of the nervous system to induce a behavioral output. In some examples, a second artificial network may be used to train the first artificial network. The second artificial network may be configured to predict the behavioral output from the individual based on the stimulation provided by the first artificial network. Parameters of the first artificial network can be adjusted using the output of the second artificial network to optimize the output signals of the first artificial network to achieve restoration and/or augmentation goals.

公开(公告)号：US20230133243A1

公开(公告)日：2023-05-04

申请号：US17995687

申请日：2021-04-12

Applicant: Fred Hutchinson Cancer Center ,  University of Washington

Inventor： Andre Lieber ,  Hans-Peter Kiem

IPC: A61K48/00 ,  A61K38/20 ,  A61K39/395 ,  A61K31/436 ,  A61K31/573 ,  A61K38/19 ,  A61K31/395 ,  A61P37/06 ,  A61P7/06

Abstract: The present disclosure provides, among other things, immune suppression regimens for in vivo gene therapy and uses thereof. In various embodiments of the present disclosure, in vivo gene therapy includes delivery of at least one exogenous coding nucleic acid sequence to a stem cell of the subject. Success of in vivo gene therapy can be inhibited or reduced by immunotoxicity. The present disclosure provides compositions and methods, including among other things immune suppression regimens, that reduce immunotoxicity of in vivo gene therapy, e.g., in vivo gene therapy including administration of a viral gene therapy vector to a subject.